{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T02:29:51Z","timestamp":1776565791082,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.mehy.2019.109321","type":"journal-article","created":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T18:01:41Z","timestamp":1563645701000},"page":"109321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Monoacylglycerol lipase inhibition as potential treatment for interstitial cystitis"],"prefix":"10.1016","volume":"131","author":[{"given":"Anu","family":"Chinnadurai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraint","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Burkovskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109321_b0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00345-009-0439-4","article-title":"Bladder pain syndrome\/interstitial cystitis: a sense of urgency","volume":"27","author":"Hanno","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1056\/NEJM191505061721802","article-title":"A rare type of bladder ulcer in women; report of cases","volume":"172","author":"Hunner","year":"1915","journal-title":"Bost Med Surg J"},{"key":"10.1016\/j.mehy.2019.109321_b0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ju.0000146114.53828.82","article-title":"Prevalence and incidence of interstitial cystitis in a managed care population","volume":"173","author":"Clemens","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.juro.2011.10.040","article-title":"Comparison of an interstitial cystitis\/bladder pain syndrome clinical cohort with symptomatic community women from the RAND interstitial cystitis epidemiology study","volume":"187","author":"Konkle","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0025","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.juro.2009.12.103","article-title":"Development, validation and testing of an epidemiological case definition of interstitial cystitis\/painful bladder syndrome","volume":"183","author":"Berry","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.juro.2006.09.032","article-title":"Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review","volume":"177","author":"Bogart","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.mehy.2019.109321_b0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2826.2008.01728.x","article-title":"The endocannabinoid system and energy metabolism","volume":"20","author":"Bellocchio","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.mehy.2019.109321_b0045","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.juro.2013.10.102","article-title":"Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis","volume":"191","author":"Wang","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","article-title":"Cannabinoid CB2 receptors in human brain inflammation","volume":"153","author":"Benito","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0055","first-page":"1092","article-title":"Evidence for novel cannabinoid receptors","volume":"106","author":"Begg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2019.109321_b0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2019.109321_b0065","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mehy.2019.109321_b0070","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ajpath.2013.08.003","article-title":"Cannabinoid receptor 2 activation: a means to prevent monocyte\u2013endothelium engagement","volume":"183","author":"Buch","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mehy.2019.109321_b0075","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.urology.2008.03.044","article-title":"Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder","volume":"72","author":"Hayn","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.mehy.2019.109321_b0080","first-page":"1939","article-title":"Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder","volume":"181","author":"Gratzke","year":"2009","journal-title":"JURO"},{"key":"10.1016\/j.mehy.2019.109321_b0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000542-200103000-00023","article-title":"Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder","volume":"94","author":"Farquhar-Smith","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.mehy.2019.109321_b0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2014.02.013","article-title":"Evaluation of selective cannabinoid CB 1 and CB 2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis","volume":"729","author":"Tambaro","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mehy.2019.109321_b0100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","article-title":"Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review","volume":"73","author":"Volkow","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.mehy.2019.109321_b0105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.brainresrev.2008.12.003","article-title":"Targeting CB2 receptors and the endocannabinoid system for the treatment of pain","volume":"60","author":"Anand","year":"2009","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.mehy.2019.109321_b0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.bjp.0707523","article-title":"CB2 receptor-mediated migration of immune cells: it can go either way","volume":"153","author":"Miller","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0120","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejphar.2006.07.016","article-title":"The cannabinoid agonist WIN 55,212\u20132 inhibits TNF-\u03b1-induced neutrophil transmigration across ECV304 cells","volume":"547","author":"Nilsson","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0130","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/cc11248","article-title":"Cannabinoid receptor 2 activation reduces intestinal leukocyte recruitment and systemic inflammatory mediator release in acute experimental sepsis","volume":"16","author":"Lehmann","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.mehy.2019.109321_b0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/npp.2014.198","article-title":"Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain","volume":"40","author":"Lomazzo","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mehy.2019.109321_b0140","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/neu.2016.4452","article-title":"Inhibition of endocannabinoid eegradation improves outcomes from mild traumatic brain injury: a mechanistic role for synaptic hyperexcitability","volume":"34","author":"Mayeux","year":"2017","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.mehy.2019.109321_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jbcpp-2012-0065","article-title":"Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut","volume":"24","author":"Kianian","year":"2013","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0150","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0026-895X(24)26516-0","article-title":"Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide","volume":"57","author":"Gonsiorek","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/biof.18","article-title":"Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand","volume":"35","author":"Sugiura","year":"2009","journal-title":"BioFactors"},{"key":"10.1016\/j.mehy.2019.109321_b0160","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1476-5381.2010.01192.x","article-title":"Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain","volume":"163","author":"Guindon","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0165","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1073\/pnas.96.21.12198","article-title":"Pain modulation by release of the endogenous cannabinoid anandamide","volume":"96","author":"Walker","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mehy.2019.109321_b0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1476-5381.2008.00029.x","article-title":"The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1","volume":"156","author":"Fowler","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0175","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.mehy.2019.109321_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1054\/plef.2001.0344","article-title":"CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids","volume":"66","author":"McAllister","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.mehy.2019.109321_b0185","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/372686a0","article-title":"Formation and inactivation of endogenous cannabinoid anandamide in central neurons","volume":"372","author":"Di Marzo","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2019.109321_b0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.mehy.2019.109321_b0195","doi-asserted-by":"crossref","first-page":"1514.e15","DOI":"10.1016\/j.urology.2009.12.051","article-title":"Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with wymptoms","volume":"75","author":"Mukerji","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.mehy.2019.109321_b0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1367-5931(03)00079-6","article-title":"Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system","volume":"7","author":"Cravatt","year":"2003","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.mehy.2019.109321_b0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1054\/plef.2001.0356","article-title":"Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance","volume":"66","author":"Sugiura","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.mehy.2019.109321_b0210","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mehy.2019.109321_b0215","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lfs.2012.10.025","article-title":"Therapeutic potential of monoacylglycerol lipase inhibitors","volume":"92","author":"Mulvihill","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.mehy.2019.109321_b0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pain.2005.12.018","article-title":"CB2 cannabinoid receptor mediation of antinociception","volume":"122","author":"Ibrahim","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.mehy.2019.109321_b0225","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1152\/ajpregu.00585.2012","article-title":"Activation of cannabinoid receptor 2 inhibits experimental cystitis","volume":"304","author":"Wang","year":"2013","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"key":"10.1016\/j.mehy.2019.109321_b0230","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bjp.0705304","article-title":"Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor","volume":"139","author":"Klegeris","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2014.02.530","article-title":"Mp17-09 Expression of monoacylglycerase (Magl) in the human lower urinary tract: a new target for intervention into the endocannabinoid system?","volume":"191","author":"Schreiber","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0240","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12031-014-0453-x","article-title":"Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase","volume":"55","author":"Wang","year":"2015","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.mehy.2019.109321_b0245","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.bmc.2014.04.057","article-title":"Identification and characterization of a new reversible MAGL inhibitor","volume":"22","author":"Tuccinardi","year":"2014","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.mehy.2019.109321_b0250","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1464-410X.2010.09583.x","article-title":"Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation","volume":"108","author":"Merriam","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.mehy.2019.109321_b0255","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/jpet.114.212753","article-title":"Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in Fatty Acid amide hydrolase wild-type and knockout mice","volume":"350","author":"Schlosburg","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.mehy.2019.109321_b0260","first-page":"145","article-title":"Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis","volume":"2","author":"Lander","year":"2014","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0265","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5489\/cuaj.10095","article-title":"Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome","volume":"5","author":"Al-Zahrani","year":"2011","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.mehy.2019.109321_b0270","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.juro.2009.06.024","article-title":"Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis\/painful bladder syndrome","volume":"182","author":"Chuang","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnsys.2018.00017","article-title":"Potential of endocannabinoids to control bladder pain","volume":"12","author":"Bjorling","year":"2018","journal-title":"Front Syst Neurosci"},{"key":"10.1016\/j.mehy.2019.109321_b0280","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/nn.2616","article-title":"Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system","volume":"13","author":"Schlosburg","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.mehy.2019.109321_b0285","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1124\/mol.110.069427","article-title":"Endocannabinoid Overload","volume":"78","author":"Lichtman","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.mehy.2019.109321_b0290","first-page":"629","article-title":"Review of intravesical therapies for bladder pain syndrome\/interstitial cystitis","volume":"4","author":"Cvach","year":"2015","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.mehy.2019.109321_b0295","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0021-9258(17)33857-7","article-title":"Purification hydrolyzing and some properties of a monoacylglycerol-enzyme of rat adipose tissue","volume":"251","author":"Tornqvist","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2019.109321_b0300","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.2337\/db06-0812","article-title":"Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity","volume":"55","author":"Bl\u00fcher","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.mehy.2019.109321_b0305","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/oby.2007.106","article-title":"Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet","volume":"16","author":"Starowicz","year":"2008","journal-title":"Obesity (Silver Spring)"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719301379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719301379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:17:42Z","timestamp":1759691862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719301379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":61,"alternative-id":["S0306987719301379"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109321","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoacylglycerol lipase inhibition as potential treatment for interstitial cystitis","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109321"}}